Physician profile
Harry J Thomas
NPI 1104086628
$583,717.41
in general payments reported to CMS, 2019-2025
44 companies · $224K in 2025
The $224K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $702 · 2021: $3,994 · 2022: $75K · 2023: $102K · 2024: $177K · 2025: $224K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $370K · Travel and Lodging: $56K · Consulting Fee: $36K · Food and Beverage: $25K · Honoraria: $15K · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $370,058.36 |
| Travel and Lodging | $56,285.37 |
| Consulting Fee | $36,329.50 |
| Food and Beverage | $24,848.26 |
| Honoraria | $15,313.82 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $180,520.10 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $173,411.60 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Lilly USA, LLC | $63,209.99 | 2023-2025 | Omvoh |
| Pfizer INC. | $51,680.05 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $45,176.48 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $18,927.95 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celltrion USA INC. | $16,079.28 | 2023-2025 | Zymfentra, Vegzelma |
| Janssen Scientific Affairs, LLC | $11,944.73 | 2019-2025 | Tremfya, Stelara, Remicade |
| Janssen Global Services, LLC | $6,709.65 | 2023 | Simponi |
| Celgene Corporation | $6,174.05 | 2021-2024 | Zeposia |
| Gastrogpo, LLC | $2,276.00 | 2023 | |
| Genzyme Corporation | $1,809.16 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,614.85 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Mahana Therapeutics, INC. | $1,050.00 | 2022 | |
| Medtronic, INC. | $326.05 | 2024-2025 | Interstim, Signia |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Anx Robotica Corp | $286.49 | 2025 | |
| Ironwood Pharmaceuticals, INC | $230.06 | 2020-2024 | Linzess |
| Aimmune Therapeutics, INC. | $211.85 | 2024-2025 | Zenpep, Vowst |
| Qol Medical, LLC | $181.58 | 2021-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $164.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $160.69 | 2020-2025 | |
| Enterra Medical, INC. | $153.61 | 2023 | |
| Daiichi Sankyo INC. | $139.35 | 2019-2022 | |
| Ardelyx, INC. | $135.39 | 2022-2025 | Ibsrela |
| Romark Laboratories, Lc | $129.97 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $103.39 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $100.94 | 2024 | Voquezna |
| Conmed Corporation | $95.43 | 2021 | |
| Intercept Pharmaceuticals, INC. | $87.51 | 2021-2023 | Ocaliva |
| Ambu INC. | $77.25 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $75.09 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $68.65 | 2023-2024 | Dificid |
| Lumendi LLC | $68.36 | 2021 | |
| Ferring Pharmaceuticals INC. | $58.77 | 2021-2023 | Rebyota |
| Braintree Laboratories, INC. | $47.68 | 2023-2025 | Sutab, Suflave |
| Novo Nordisk INC | $40.97 | 2019-2025 | Wegovy |
| Organon LLC | $29.88 | 2024-2025 | Hadlima |
| Amgen INC. | $26.34 | 2022 | |
| Sandoz INC. | $25.18 | 2023 | Hyrimoz |
| Redhill Biopharma INC. | $24.97 | 2021-2023 | Talicia |
| Boston Scientific Corporation | $24.04 | 2021 | |
| Shield Therapeutics INC | $21.89 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.44 | 2023 | |
| Allergan, INC. | $15.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,796.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.